Our Lab on the News: Intragenic Rearrangement Could Hold the Key to Improved Immunotherapy
A new discovery from our lab reveals that tumors with a high intragenic rearrangement (IGR) burden may respond more favorably to immune checkpoint blockades, offering a new hope for cancer patients that have a low tumor mutation burden. This discovery may pave the way to more effective immunotherapy treatments in the future.
See News Releases:
A new genetic biomarker to predict immunotherapy success
Drug Target Review,
Tumours with a greater IGR burden could respond better to immune checkpoint blockades, advancing precise treatments for patients.
New test could predict immunotherapy responders for broader range of cancers than current tools
MedicalXpress,
A newly identified genetic marker could potentially predict which patients are likely to respond to immunotherapy in cancer…
New test could predict immunotherapy responders for broader range of cancers than current tools
EurekAlert!,
image: Xiaosong (Johnathan) Wang, M.D., Ph.D., associate professor of pathology at the University of Pittsburgh and UPMC…
New test could predict immunotherapy responders for broader range of
ScienMag,
A newly identified genetic marker could potentially predict which patients are likely to respond to immunotherapy in cancer…
New test could predict immunotherapy responders for broader range of cancers than current tools
Bioengineer.org,
A newly identified genetic marker could potentially predict which patients are likely to respond to immunotherapy in cancer…
Novel Test Predicts More Immunotherapy Responders in Cancer
Mirage News,
A newly identified genetic marker could potentially predict which patients are likely to respond to immunotherapy in cancer…